Carregant...
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review,...
Guardat en:
| Publicat a: | Cancer Biol Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Chinese Anti-Cancer Association
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4850130/ https://ncbi.nlm.nih.gov/pubmed/27144064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|